1. Introduction {#sec1-molecules-25-03465}
===============

G-quadruplexes (G4s) are four-stranded secondary structures formed in guanine-rich nucleic acids \[[@B1-molecules-25-03465]\]. The building block of G4s is the G-tetrad, consisting of four guanines connected through Hoogsteen hydrogen bonds in a cyclic coplanar arrangement \[[@B2-molecules-25-03465]\]. A G4 structure is formed when two or more G-tetrad planes stack on top of each other and is stabilized by physiological relevant monovalent cations, especially K^+^ \[[@B3-molecules-25-03465],[@B4-molecules-25-03465],[@B5-molecules-25-03465]\]. The biologically relevant intramolecular G4s are globular nucleic acid structures with unique folding and capping structures that provide an opportunity for selective targeting by small molecules \[[@B6-molecules-25-03465],[@B7-molecules-25-03465],[@B8-molecules-25-03465]\].

G4 structures are involved in many cellular processes of DNA, including gene transcription \[[@B9-molecules-25-03465],[@B10-molecules-25-03465]\], DNA replication \[[@B11-molecules-25-03465]\], and genome stability \[[@B12-molecules-25-03465],[@B13-molecules-25-03465]\]. In the human genome, G4 structures are prevalent in the regulatory regions and enriched in the promoters of cancer-related genes \[[@B14-molecules-25-03465],[@B15-molecules-25-03465]\]. In particular, MYC, one of the most deregulated oncogenes in human cancer, has a DNA-G4 forming motif (MycG4) in its promoter \[[@B9-molecules-25-03465],[@B16-molecules-25-03465],[@B17-molecules-25-03465],[@B18-molecules-25-03465],[@B19-molecules-25-03465],[@B20-molecules-25-03465]\]. Compounds that bind and stabilize the MycG4 structure have been shown to repress MYC expression and lead to cancer cell death \[[@B8-molecules-25-03465],[@B9-molecules-25-03465],[@B16-molecules-25-03465]\]. Therefore, the MycG4 is considered an attractive target for anticancer drugs. However, over 10,000 G4 structures have been discovered in human chromatin of precancerous cells \[[@B15-molecules-25-03465],[@B21-molecules-25-03465]\]. It is thus important to determine the selectivity of a G4-targeting compound.

3,6-bis(1-Methyl-4-vinylpyridinium) carbazole diiodide (BMVC, [Figure 1](#molecules-25-03465-f001){ref-type="fig"}a) is a G4-interactive compound and the first fluorescent probe (λ~ex,max~ = 435, λ~em,max~ = 580) to detect G4 structures in human cells \[[@B22-molecules-25-03465],[@B23-molecules-25-03465],[@B24-molecules-25-03465]\]. BMVC has also been developed as a potential fluorescent marker for cancer cells \[[@B25-molecules-25-03465],[@B26-molecules-25-03465]\]. Whereas BMVC was first developed to detect G4 structures in human telomeres, our recent study shows that BMVC binds the MYC promoter G4 (MycG4, [Figure 1](#molecules-25-03465-f001){ref-type="fig"}b) with higher selectivity and affinity \[[@B27-molecules-25-03465]\]. We have determined the solution structures of BMVC-MycG4 complexes, which show that BMVC binds to the MycG4 via multiple interactions, including stacking external G-tetrads, recognition of the MycG4-flanking bases, and conformational adjustment of the BMVC molecule. Moreover, our results show BMVC represses MYC expression in a human breast cancer cell line. However, the binding selectivity of BMVC to potential G4s formed in the human chromatin has not been broadly examined.

Microarray glass slides with hundred thousands of DNA sequences are a fast, straightforward, and high-throughput platform that has been employed to screen, profile, and quantify ligand and protein interactions with DNA and RNA molecules \[[@B28-molecules-25-03465],[@B29-molecules-25-03465],[@B30-molecules-25-03465]\]. We have very recently designed custom DNA microarrays that can assess the binding selectivities of proteins, small molecules, and antibodies across over 15,000 potential G4 structures \[[@B31-molecules-25-03465]\].

Herein, we report a binding-selectivity analysis of BMVC to the MycG4 and other G4 structures using custom G4 microarrays and competition experiments between Cy5-fluorophore (λ~ex,max~ = 647, λ~em,max~ = 665) labeled small molecule pyridostatin \[[@B32-molecules-25-03465]\] (Cy5-PDS) and unlabeled BMVC. Our results show that BMVC differentially binds to various G4 structures and has a different G4 selectivity profile from Cy5-PDS. BMVC shows preferential binding to the MycG4 among the known G4 structures. Moreover, the microarray data reveals the sequence selectivity of BMVC to the flanking residues of the MycG4, especially at the 3′-end. The large-scale microarray results are confirmed by orthogonal small-scale NMR and fluorescence binding analyses. This is the first large-scale study of a G4-interactive ligand that shows a high-throughput evaluation of G4-binding selectivity and sequence specificity with unbiased selection of G4 sequences. It demonstrates the potential of custom DNA microarrays in the development of drugs targeting DNA or RNA structures.

2. Results {#sec2-molecules-25-03465}
==========

2.1. BMVC Binds G4 Sequences Differently from PDS {#sec2dot1-molecules-25-03465}
-------------------------------------------------

We have designed custom G4 microarrays that contain a total of 19,249 G4 DNA sequences \[[@B31-molecules-25-03465]\]. The G4 microarrays were created by covalently attaching thousands of unique G4-forming DNA 60-mers to a glass surface. Pyridostatin (PDS) is a known G4-interactive compound. Measured by the fluorescence intensity of Cy5-PDS bound to each sequence in potassium-containing solution, Cy5-PDS was shown to preferentially bind G4-forming sequences on the G4 microarrays \[[@B31-molecules-25-03465]\]. To test the binding selectivity of BMVC, we performed competition experiments using custom G4 microarrays ([Figure 1](#molecules-25-03465-f001){ref-type="fig"} and [Figure S1](#app1-molecules-25-03465){ref-type="app"}). The addition of potassium-containing solution to G4-forming oligonucleotides induced G4 formation. Subsequently, the microarrays were incubated with 1 µM Cy5-PDS in the absence or presence of 1 µM, 3 µM, or 10 µM of the unlabeled BMVC molecule. After washing to remove the unbound Cy5-PDS and BMVC, the fluorescence intensities of Cy5-PDS bound to DNA oligonucleotides were detected using a fluorescence scanner. The binding selectivity of BMVC to different G4 structures was assessed by measuring the relative fluorescence intensity reduction of Cy5-PDS as BMVC concentration increased.

The fluorescence intensities of 1 µM Cy5-PDS in the presence of various concentrations of unlabeled BMVC were plotted against the fluorescence intensities in the absence of BMVC ([Figure 1](#molecules-25-03465-f001){ref-type="fig"}c). The competition experiment of 1 µM Cy5-PDS with 1 µM of unlabeled PDS was performed as the positive control ([Figure S2](#app1-molecules-25-03465){ref-type="app"}). For a compound that competitively binds all sequences with the same affinity as Cy5-PDS, the competition experiments of 1 µM Cy5-PDS with various concentrations of the unlabeled compound will follow the predicted linear relationships ([Figure 1](#molecules-25-03465-f001){ref-type="fig"}d). Furthermore, fluorescence intensities of Cy5-PDS bound to various G4 sequences will uniformly decrease in a dose-dependent manner, as presented by decreased slopes ([Figure 1](#molecules-25-03465-f001){ref-type="fig"}d). In the competition experiment, the unlabeled BMVC could compete with the Cy5-PDS binding to G4 sequences in a dose-dependent manner ([Figure 1](#molecules-25-03465-f001){ref-type="fig"}c). However, the binding profile of BMVC was different from unlabeled PDS. Selectivity can be better assessed at equimolar concentrations of unlabeled ligand and Cy5-PDS (both 1 µM) ([Figure 1](#molecules-25-03465-f001){ref-type="fig"}c, left and [Figure S2](#app1-molecules-25-03465){ref-type="app"}). BMVC displays a more pronounced binding selectivity to different G4 sequences, as shown by a larger deviation from linear relationships, particularly with the stable-G4 forming sequences (at higher fluorescence intensities, [Figure 1](#molecules-25-03465-f001){ref-type="fig"}c, left). Unlabeled PDS appears to bind less selectively to the G4 sequences than BMVC, as shown by the stronger competition at the weaker Cy5-PDS-bound sequences (non-G4 sequences) (at lower fluorescence intensities, [Figure S2](#app1-molecules-25-03465){ref-type="app"}).

2.2. BMVC Shows Different Binding Selectivity to Various G4 Structures as Compared to PDS {#sec2dot2-molecules-25-03465}
-----------------------------------------------------------------------------------------

To determine the G4-binding selectivity of BMVC, we examined the BMVC binding to known G4 structures, including 7 well-studied MYC promoter G4 sequences, 15 other oncogene promoter G4 sequences, and 3 human telomeric G4 sequences ([Table 1](#molecules-25-03465-t001){ref-type="table"}). BMVC competes with the binding of Cy5-PDS to most G4 sequences in a dose-dependent manner as indicated by reduced fluorescence intensities ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}a).

Comparison of the inhibitory effects for the known G4 structures revealed differential G4 binding selectivity of BMVC vs. Cy5-PDS ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}b). We first ranked G4 sequences based on the fluorescence intensity of bound Cy5-PDS. As illustrated in [Figure 2](#molecules-25-03465-f002){ref-type="fig"}a (blue bars), Cy5-PDS prefers long and highly G-rich sequences, such as PDGF-A_Pu48, PDGFRb_Pu41, and MYC_Pu40. In addition, it also binds well to parallel G4s, such as Bcl-2_55G, Bcl-2_P1G4, VEFG, and various MYC G4s. For most G4s, the fluorescence intensity of 1 µM Cy5-PDS was reduced by 50% upon equimolar addition of BMVC ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}b), suggesting a similar binding affinity of BMVC and Cy5-PDS to these G4s. However, the binding of BMVC was much weaker for the PDGF-A_Pu48 and MYB sequences than the binding of Cy5-PDS ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}b). Both PDGF-A_Pu48 and MYB sequences have no-5′-flanking, while MYB forms a tetrad-heptad structure \[[@B54-molecules-25-03465]\], whereas the optimal binding of BMVC requires a flanking base at both the 5′-end and 3′-end, as shown by NMR solution structural study of the BMVC-MycG4 complex \[[@B27-molecules-25-03465]\] ([Figure S3](#app1-molecules-25-03465){ref-type="app"}).

Cy5-PDS binds strikingly poor to nonparallel G4s, such as human telomeric G4s, which show less than 25% fluorescence intensity as compared to parallel-stranded G4s ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}b). BMVC significantly inhibited the binding of Cy5-PDS to human telomeric G4s ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}b), indicating a stronger binding of BMVC to the human telomeric G4s as compared to PDS. However, fluorescence measurements showed that BMVC binds parallel G4s, such as MYC and VEGF G4s, much stronger than the human telomeric G4s ([Figure S4](#app1-molecules-25-03465){ref-type="app"}). Therefore, the microarray competition result indicates that Cy5-PDS binds the human telomeric G4s even weaker than BMVC.

2.3. BMVC Preferentially Binds to MYC_14/23T among the Known G4 Structures {#sec2dot3-molecules-25-03465}
--------------------------------------------------------------------------

In general, Cy5-PDS and BMVC both strongly bind to parallel G4s ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}b). Intriguingly, among all parallel G4s, BMVC induced largest reduction of the Cy5-PDS binding to the MYC_14/23T G4. It is important to note that Cy5-PDS also binds the MYC_14/23T G4 sequence very well ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}a), therefore the strongest competition effect demonstrates that BMVC selectively recognizes the MYC_14/23T G4. The MYC promoter G4 is the best-studied promoter G-quadruplex structure and a prototype of parallel G4s \[[@B8-molecules-25-03465]\]. Notably, MYC_14/23T and MYC_Pu22 form the same parallel G4 ([Figure 1](#molecules-25-03465-f001){ref-type="fig"}b) except for the 3′-end flanking residue, which is a T in MYC_14/23T and a G in MYC_Pu22 \[[@B35-molecules-25-03465]\]. The strikingly stronger binding of BMVC to MYC_14/23T than MYC_Pu22 ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}b) indicates that BMVC selectively recognizes the 3′-flanking T of MYC_14/23T G4.

2.4. BMVC Selectively Recognizes the Flanking Sequences of Parallel G4s, Especially the 3′-Flanking T {#sec2dot4-molecules-25-03465}
-----------------------------------------------------------------------------------------------------

To examine the preference of BMVC for specific flanking sequences, we analyzed the binding of BMVC to MYC G4-derived sequence variants of the two flanking bases at both ends (5′-NNGGGTGGGGAGGGTGGGNN-3′) using the competition microarray experiments. The differential reduction of Cy5-PDS binding to variants in the flanking sequences induced by BMVC addition reveals the binding selectivity for specific MYC G4 flanking sequences ([Figure 3](#molecules-25-03465-f003){ref-type="fig"}a). In the absence of BMVC, Cy5-PDS exhibits a slight preference for the 3′-flanking C and T, as shown by the most-bound (top 10%) and least-bound (bottom 10%) flanking variants ([Figure 3](#molecules-25-03465-f003){ref-type="fig"}b, top panel). The addition of BMVC significantly altered the most and least Cy5-PDS-bound flanking variants, with a clearly stronger selectivity at the 3′-end than at the 5′-end ([Figure 3](#molecules-25-03465-f003){ref-type="fig"}b, middle and bottom panels). The most and least Cy5-PDS-bound flanking variants in the presence of equimolar BMVC reveal the binding selectivity of BMVC. Particularly, thymine became markedly less enriched in the top 10% Cy5-PDS most-bound 3′-flanking variants but significantly enriched in the bottom 10% Cy5-PDS least-bound variants, indicating that BMVC strongly prefers the MYC G4 with the 3′-flanking T. On the other hand, C is the least-favored flanking base for BMVC binding at both the 3′- and 5′- ends, as shown by the greater enrichment in the top 10% Cy5-PDS most-bound flanking variants.

We further analyzed the effects of BMVC on the Cy5-PDS-binding to MYC G4 loop and single flanking-base sequence variants (5′-NGGGNGGGNNGGGNGGGN-3′), which include all possible loop and flanking variants ([Figure 3](#molecules-25-03465-f003){ref-type="fig"}c). Consistent with the two-base-flanking variants, the results showed BMVC strongly preferred the 3′-end flanking T but disfavored the flanking C at both ends. In contrast, Cy5-PDS preferred C for all three loops and the 3′-end flanking. It is noted that the MYC G4 single flanking-base variants all contain additional 3′-flanking bases for linking the G4 oligos to the microarray plates.

The sequence selectivity shown by the flanking variants explains the markedly weaker binding of BMVC to Bcl-2_P1G4 ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}). Bcl2_55G and Bcl-2_P1G4 both form parallel G4s with a long central loop (13-nt long in Bcl2_55G and 12-nt long in Bcl-2_P1G4) but different flanking sequences \[[@B47-molecules-25-03465],[@B48-molecules-25-03465]\]. However, whereas BMVC showed good binding to Bcl2_55G similar to other parallel G4s, the binding to Bcl-2_P1G4 was markedly weaker ([Figure 2](#molecules-25-03465-f002){ref-type="fig"}a,b). Bcl-2_P1G4 has a flanking C at both the 5′- and 3′- ends and only contains a short 1-nt flanking at the 5′-end, suggesting that BMVC disfavors the flanking C and short flanking.

2.5. NMR Binding Experiments Confirm the Binding Selectivity of BMVC to G4 Structures and Flanking Sequences {#sec2dot5-molecules-25-03465}
------------------------------------------------------------------------------------------------------------

The binding selectivity of BMVC to G4 structures and flanking sequences was confirmed by NMR titration experiments of BMVC to different G4 sequences, including parallel-stranded MYC_14/23T G4 and its 5′- and 3′-flanking variants, VEGF and MYC1234 G4s, basket-type human telomeric G4 (wtTel22 in Na^+^), and hybrid type human telomeric G4 (Tel26 in K+) ([Figures S5 and S6](#app1-molecules-25-03465){ref-type="app"}). BMVC binds best to the MYC_14/23T G4, as indicated by well-resolved imino proton peaks for BMVC complexes ([Figure S5a](#app1-molecules-25-03465){ref-type="app"}). Our previous NMR solution structural study shows that BMVC binds at both ends of the MYC_14/23T G4 to form a 2:1 complex \[[@B27-molecules-25-03465]\] ([Figure S3](#app1-molecules-25-03465){ref-type="app"}). Mutations at the 5′-flanking sequence do not affect the binding of BMVC at the 5′-end ([Figure S6c--e](#app1-molecules-25-03465){ref-type="app"}). In contrast, the 3′-end binding of BMVC is sensitive to the mutations at the 3′-flanking sequence, with a clear preference for the 3′-flanking T ([Figure S6b](#app1-molecules-25-03465){ref-type="app"}). In addition, BMVC prefers at least two flanking bases for a specific binding ([Figure S6](#app1-molecules-25-03465){ref-type="app"}). These results are in good agreement with the DNA microarray data ([Figure 3](#molecules-25-03465-f003){ref-type="fig"}).

While BMVC binds the MYC_14/23T G4 with the highest affinity ([Figure S4](#app1-molecules-25-03465){ref-type="app"}), BMVC can bind well to other parallel G4s, such as MYC1234 and VEGF G4 ([Figure S5b,d](#app1-molecules-25-03465){ref-type="app"}). Additionally, BMVC favors the 5′-flanking A of parallel G4s, as indicated in the NMR titration data of the VEGF G4 flanking variants ([Figure S5c,d](#app1-molecules-25-03465){ref-type="app"}). However, BMVC did not show specific binding to the basket-type or hybrid-type human telomeric G4s ([Figure S5e,f](#app1-molecules-25-03465){ref-type="app"}). These results are consistent with the G4 microarray data.

3. Conclusions {#sec3-molecules-25-03465}
==============

We have established a high-throughput, large-scale custom G4 DNA microarray to assess the binding selectivities of proteins and small molecules across \~20,000 potential G4 structures simultaneously. Competition binding experiments of the Cy5 labeled PDS and the unlabeled G4-interactive small molecule BMVC demonstrate that the custom G4 microarray platform can assess the binding selectivity of BMVC to various G4 structures and flanking sequences, as well as differential G4 binding selectivity between BMVC and PDS. Our results reveal that BMVC selectively binds parallel G4s, in particular the MYC_14/23T G4. Moreover, the G4 microarray data shows BMVC selectively recognizes the flanking sequences of parallel G4s, especially the 3′-flanking T. Importantly, the binding and sequence selectivity revealed by the large-scale DNA microarray data is in good agreement with the individual binding data by NMR and fluorescence. Our study demonstrates that the G4 DNA microarray provides a high-throughput and unbiased platform to assess the binding selectivity of G4-targeting molecules on a large scale and can help understand the properties that govern molecular recognition.

4. Materials and Methods {#sec4-molecules-25-03465}
========================

4.1. Custom G4 DNA Microarray Design {#sec4dot1-molecules-25-03465}
------------------------------------

We designed a custom microarray that contains four identical sectors that contain \~177,440 ssDNA 60-mers to examine G4 binding selectivity (NCBI GEO Platform GPL28372). The microarray contains different sets of G4 variants designed to examine several sequence parameters that affect G4 formation and binding selectivity such as loop length, loop sequence, flanking tail sequence, and single nucleotide variants of known G4s \[[@B31-molecules-25-03465]\]. Briefly, the array includes a set of sequences from human telomeres and oncogene promoters known to form G4s with various topologies as positive controls ([Table 1](#molecules-25-03465-t001){ref-type="table"}) as well as a set of 295 additional G4-forming sequences from the literature \[[@B57-molecules-25-03465]\]. Loop and flanking tail sequences were varied using A, T, G, and C polynucleotide stretches and a subset of combinations, described in \[[@B31-molecules-25-03465]\]. For the flanking variants, we generated 256 versions of the major MYC G4 with all possible dinucleotide flanking sequences (5′-NNGGGTGGGGAGGGTGGGNN-3′). For the loop sequence variants, we generated 4,096 sequences of the form 5′-NGGGNGGGNNGGGNGGGN-3′. Negative controls include 19 oncogene G4s in which all G-tracts are replaced with either A, T, or C, reverse complements of G4 sequences, as well as a set of 86 published non-G4 sequences \[[@B57-molecules-25-03465]\].

4.2. DNA Microarray Binding Experiments {#sec4dot2-molecules-25-03465}
---------------------------------------

DNA microarray experiments were performed and analyzed as described previously \[[@B31-molecules-25-03465]\]. Microarrays were preincubated with a pH 7.4 phosphate buffer solution with 100 mM potassium for 1 h at room temperature to induce G4 formation. Arrays then were blocked with 4% nonfat dry-milk in a potassium phosphate buffer before incubation with small molecules (Cy5-PDS, Cy5-PDS+BMVC, or Cy5-PDS+PDS) for 1 h at room temperature.

4.3. Data Processing and Analysis {#sec4dot3-molecules-25-03465}
---------------------------------

Molecule-bound microarrays were scanned with an Agilent G5761A SureScan Dx Microarray Scanner System to detect Cy5 signal at two laser settings (30 and 100 PMT). Spot intensities from microarray images were extracted using Agilent Feature Extraction Software and are reported as raw fluorescence intensities. All binding assays were performed twice with high agreement between replicates (R \> 0.8). Microarrays with the fewest number of saturated spots were used for further analysis. Median intensity was then computed for probes containing identical sequence on each microarray. Sequence logos were generated from a position frequency matrix generated from selected sequences using ggseqlogo \[[@B58-molecules-25-03465]\].

4.4. NMR Spectroscopy Experiments {#sec4dot4-molecules-25-03465}
---------------------------------

G4 DNA oligonucleotides were synthesized using β-cyanoethylphosphoramidite solid-phase chemistry (Applied Biosystem Expedite 8909), as described previously \[[@B36-molecules-25-03465]\]. NMR experiments were performed on a Bruker AV-III-500-HD equipped with a BBFO Z-gradient cryoprobe. DNA samples were heated to 95 °C for 5 min, then cooled slowly for G4 formation. For the 1D 1H NMR experiments, samples contained 100--250 μM DNA in an appropriate buffer solution with 10% D2O for the lock. The titrations were performed by adding increasing amounts of the compounds to the DNA samples in solution.
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The following are available online. Figure S1: Comparison of replicate fluorescence intensity of Cy5-PDS in the absence and presence of 1, 3, and 10 µM of BMVC; Figure S2: Competition microarray experiments of Cy5-PDS with unlabeled PDS; Figure S3: NMR solution structure of the 2:1 complex of BMVC and MYC_14/23T G4 (PDB ID: 6O2L); Figure S4: Apparent dissociation constant (Kd, app) of BMVC binding to various G4s; Figure S5: 1D 1H NMR titration spectra of BMVC with various G4 sequences; Figure S6: 1D 1H NMR titration spectra of BMVC with MYC_14/23T flanking variants.
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![The binding of 3,6-bis(1-Methyl-4-vinylpyridinium) carbazole diiodide (BMVC) to various G4 structures differs from pyridostatin (PDS). (**a**) Chemical structure of BMVC. (**b**) MycG4, the major G-quadruplex formed in the MYC promoter NHE III~1~ in K^+^ solution, a parallel-stranded G4 structure. (**c**) Competition experiments of DNA microarrays with thousands of G4 sequences showing the differential binding of BMVC to various G4s as compared to Cy5-fluorophore (λ~ex,max~ = 647, λ~em,max~ = 665) labeled small molecule pyridostatin (Cy5-PDS), as shown by Cy5-PDS fluorescence intensity. The competition experiments were performed in the presence of 1, 3, and 10 µM BMVC. The black dashed lines represent predicted linear relationships when the binding affinities of BMVC and PDS are the same. G4-containing sequences are shown in blue spots. Non-G4 forming sequences are shown in orange spots and serve as negative controls. Each spot represents the average of two independent measurements ([Figure S1](#app1-molecules-25-03465){ref-type="app"}). (**d**) Schematic diagram showing the predicted linear relationships when the competitor has the same binding affinities as Cy5-PDS. The competition effects can be revealed by a dose-dependent slope reduction.](molecules-25-03465-g001){#molecules-25-03465-f001}

![The binding preference of BMVC to known G4 structures. Among the known G4 structures, BMVC prefers to bind to MYC_14/23T, 5′-TGAGGGTGGGTAGGGTGGGTAA-3′ (highlighted by yellow shade). Telomeric sequences are known to form nonparallel structures \[[@B42-molecules-25-03465],[@B43-molecules-25-03465],[@B44-molecules-25-03465],[@B45-molecules-25-03465],[@B46-molecules-25-03465]\] and are poorly bound by Cy5-PDS (shaded in gray). (**a**) The competition microarray experiments showing dose-dependent inhibitory effects of BMVC on the binding of Cy5-PDS to various known G4 structures. The G4 sequences are shown in [Table 1](#molecules-25-03465-t001){ref-type="table"}. *n* = 2 to 20 independent measurements. Error bars represent mean ± SD. (**b**) BMVC has different inhibitory effects on the binding of Cy5-PDS to the known G4 structures at the equal molar concentration (1 µM). *n* = 2 to 20 independent measurements. Error bars represent mean ± SD.](molecules-25-03465-g002){#molecules-25-03465-f002}

![The binding selectivity of BMVC for the flanking sequences of MYC G4. (**a**) An illustration of binding logo analysis for Cy5-PDS signal with the competition of 1 µM BMVC on MYC G4-derived sequences 5′-[NN]{.ul}GGGTGGGGAGGGTGGG[NN]{.ul}-3′ (256 total sequences). (**b**) The inhibitory effects of BMVC on the binding of Cy5-PDS to MYC G4-derived sequences with variant 5′- and 3′- flanking segments (5′-[NN]{.ul}GGGTGGGGAGGGTGGG[NN]{.ul}-3′). (**c**) The inhibitory effects of BMVC on the binding of Cy5-PDS to MYC G4-derived sequences 5′-[N]{.ul}GGG[N]{.ul}GGG[NN]{.ul}GGG[N]{.ul}GGG[N]{.ul}-3′, (4096 total sequences), which include all possible loop and flanking variants.](molecules-25-03465-g003){#molecules-25-03465-f003}

molecules-25-03465-t001_Table 1

###### 

G4 sequences analyzed in [Figure 2](#molecules-25-03465-f002){ref-type="fig"}.

  Name                                                                                      G4 Sequence (5′→3′)
  ----------------------------------------------------------------------------------------- --------------------------------------------------
  MYC_Pu40 \[[@B9-molecules-25-03465]\]                                                     TTATGGGGAGGGTGGGGAGGGTGGGGAAGGTGGGGAGGAG
  MYC_Pu29 \[[@B9-molecules-25-03465]\]                                                     TTGGGGAGGGTGGGGAGGGTGGGGAAGGT
  MYC_Pu27 \[[@B9-molecules-25-03465]\]                                                     TGGGGAGGGTGGGGAGGGTGGGGAAGG
  MYC_Pu26 \[[@B33-molecules-25-03465],[@B34-molecules-25-03465]\]                          TTGGGGAGGGTGGGGAGGGTGGGGAA
  MYC_Pu22 \[[@B35-molecules-25-03465],[@B36-molecules-25-03465]\]                          TGAGGGTGGGGAGGGTGGGGAA
  MYC_14/23T \[[@B35-molecules-25-03465],[@B36-molecules-25-03465]\]                        TGAGGGTGGGTAGGGTGGGTAA
  MYC_Pu18 \[[@B37-molecules-25-03465]\]                                                    AGGGTGGGGAGGGTGGGG
  PDGFRβ_Pu41 \[[@B38-molecules-25-03465]\]                                                 GCTGGGAGAAGGGGGGGCGGCGGGGCAGGGAGGGTGGACGC
  PDGFRβ-5′end \[[@B38-molecules-25-03465]\]                                                TTGGGAGAAGGGGGGGCGGCGGGGCA
  PDGFRβ-5′mid-vac \[[@B39-molecules-25-03465]\]                                            AAGGGAGGGCGGCGGGGCA
  PDGFRβ-3′mid \[[@B40-molecules-25-03465]\]                                                AAGGGGGGGCGGCGGGGCAGGGAGGGT
  PDGFRβ-3′end \[[@B41-molecules-25-03465]\]                                                CGGCGGGGCAGGGAGGGTGGACG
  wtTel22 \[[@B42-molecules-25-03465]\]                                                     AGGGTTAGGGTTAGGGTTAGGG
  Tel26 \[[@B43-molecules-25-03465],[@B44-molecules-25-03465],[@B45-molecules-25-03465]\]   TTAGGGTTAGGGTTAGGGTTAGGGAAA
  wtTel26 \[[@B45-molecules-25-03465],[@B46-molecules-25-03465]\]                           TTAGGGTTAGGGTTAGGGTTAGGGTTA
  Bcl-2_55G \[[@B47-molecules-25-03465]\]                                                   AGGGGCGGGCGCGGGAGGAAGGGGGCGGGA
  Bcl-2_P1G4 \[[@B48-molecules-25-03465]\]                                                  CGGGCGGGAGCGCGGCGGGCGGGCGGGC
  PDGF-A_Pu48 \[[@B49-molecules-25-03465]\]                                                 GGAGGCGGGGGGGGGGGGGCGGGGGCGGGGGCGGGGGAGGGGCGCGGC
  KRAS \[[@B50-molecules-25-03465]\]                                                        AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGGCAG
  KRAS_NMR \[[@B51-molecules-25-03465]\]                                                    AGGGCGGTGTGGGAATAGGGAA
  VEGF \[[@B52-molecules-25-03465]\]                                                        CGGGGCGGGCCGGGGGCGGGGT
  RET \[[@B53-molecules-25-03465]\]                                                         GGGTAGGGGCGGGGCGGGGCGGGGGC
  MYB \[[@B54-molecules-25-03465]\]                                                         GGAGGAGGAGGTCACGGAGGAGGAGGAGAAGGAGGAGGAGGA
  HIF1a \[[@B55-molecules-25-03465]\]                                                       GGGAGGGAGAGGGGGCGGG
  c-KIT \[[@B56-molecules-25-03465]\]                                                       AGGGAGGGCGCTGGGAGGAGGG

[^1]: These authors contributed equally.
